Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05632354 · ClinicalTrials.gov registry record · Phase 2
GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT05632354 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 47 participants.
The verdict
NCT05632354, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
An Open-label Extension Study of GBT021601 in Participants with Sickle Cell Disease
Interventions
- DRUG Osivelotor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2023-01-05 |
| Est. Completion | 2025-02-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05632354
The ClinicalTrials.gov registry entry for NCT05632354 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Osivelotor is the first listed.
NCT05632354 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05632354 about?
NCT05632354 is a clinical study titled "GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)". An Open-label Extension Study of GBT021601 in Participants with Sickle Cell Disease
What is the current status of trial NCT05632354?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2023-01-05. Estimated completion is 2025-02-13.
What interventions are being tested in trial NCT05632354?
The interventions under investigation include: Osivelotor (DRUG).
Who is sponsoring clinical trial NCT05632354?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.